There are no clear conclusive clinical reports defining the adequate effective dose of
midazolam in patients undergoing day-case esophageal-gastro-duodenoscopy (EGD). Defining such
dosage will facilitate practitioners who are not anesthesia professionals to administer
sedative drugs to establish a satisfactory level of moderate sedation. Our first aim is to
determine the effective dose for 90% of patients (ED 90) of midazolam undergoing day-case
EGD.